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The bioconjugation of proteins with small molecules has proved an invaluable strategy for probing and
perturbing biological mechanisms. The general use of chemical methods for protein functionalisation
can be limited however by the requirement for complicated reaction partners to be present in large
excess, and harsh conditions which are incompatible with many protein scaffolds. Herein we describe
a site-selective organocatalyst-mediated protein aldol ligation (OPAL) that affords stable carbon–carbon
linked bioconjugates at neutral pH. OPAL enables rapid modification of proteins using simple aldehyde
probes in minimal excess, and is utilised here in the affinity tagging of proteins in cell lysate. Furthermore
we demonstrate that the b-hydroxy aldehyde OPAL product can be functionalised again at neutral pH in
a tandem organocatalyst-mediated oxime ligation. This tandem strategy is showcased in the ‘chemical
mimicry’ of a previously inaccessible natural dual post-translationally modified protein integral to the
pathogenesis of the neglected tropical disease Leishmaniasis.Introduction
Protein-small molecule bioconjugates have revolutionised the
elds of chemical medicine, chemical biology and cell
biology,1–4 but their utility can be undermined by the instability
of the covalent linkages generated by existing protein chemical
modication strategies.5 Carbon–carbon bonds, the backbone
of all organic molecules, are inherently stable across a range of
conditions however, and are therefore established as the most
coveted linkage in bioconjugation studies. Although a small
number elegant strategies for the chemical assembly of protein
C–C bonds, including carbon free-radical additions to
alkenes,6,7 Knoevenagel8 or Mukaiyama9 based condensations,
and Pictet–Spengler type ligations,10 in addition to other bio-
orthogonal ligations,3,11–13 have recently demonstrated impact
beyond academic labs, the general use of some such methods
can be hindered by practical limitations. These include the
requirement for chemical probes containing reactive handles
accessible only through multi-step syntheses, or probes them-
selves which are prohibitively expensive and used in largerk, York, YO10 5DD, UK. E-mail: martin.
York, YO10 5DD, UK
tion (ESI) available. See DOI:
hemistry 2018excess, or have reduced reactivity under biological conditions
such as in the presence of oxygen. Of particular signicance is
the frequent requirement for acidic or basic pH during bio-
conjugation as the folding, stability and function of many
proteins (and complexes) depends on the maintenance of a pH
close to neutral. Deviations from this optimal pH window can
therefore have deleterious effects14 exemplied by the disas-
sembly of the histone octamer nucleosome core,15 human
hemoglobin dissociation,16 aggregation of antibodies17 and
protein aggregation events associated with neurodegenerative
diseases such as Alzheimer's18 and Prion diseases.19 Indeed,
acidic pH is a characteristic feature of the lysosome which
facilitates the degradation of proteins. There is therefore
a pressing need to develop fully biocompatible ligations that
address these limitations and enable efficient C–C bio-
conjugation of proteins at neutral pH. Using affordable simple
probes in ratios acceptable for small molecule chemistry would
also allow wider access to the methodology in non-specialist
labs or those with limited resources.
In comparison to bioconjugation chemistry the synthesis of
C–C bonds in small molecule chemistry is well established, and
in the 2000's was redened by the emergence of ‘organo-
catalysts’20,21 capable of optimising existing transformations as
well as inspiring new reactions.22,23 Our interest in this area was
piqued by the prominent role aldehyde chemistry has played in
the exponential development of the eld.24 This is notable as
aldehydes are chemical handles which are easily installed intoChem. Sci., 2018, 9, 5585–5593 | 5585
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View Article Onlineproteins through modication of both natural25,26 and unnat-
ural amino acids,27 with efficiencies akin to the installation of
widely utilised protein modication tags such as dehy-
droalanine (from cysteine7,28 or phosphoserine6) and azides or
alkynes.29 We therefore sought to explore whether the chal-
lenges of constructing C–C modied proteins could be over-
come through exploitation of aldehyde handles, and the
development of a novel ligation which merged established
small molecule aldehyde organocatalysis methods with devel-
oping bioconjugation chemistry techniques.
We were attracted to Northrup and Macmillan's seminal
work on cross aldol reactions of aldehydes using L-proline 1 as
an organocatalyst,30 and the water compatibility of this
chemistry.31 We envisioned that an analogous cross aldol
reaction on protein aldehydes might have widespread utility
because it would enable site selective C–C modication of
proteins using uncomplicated aldehyde probes and non-toxic
affordable organocatalysts. As an additional benet, we
anticipated the b-hydroxy aldehyde product of the cross aldol
reaction could be subjected to alternative aldehyde ligation
conditions to afford dual modied proteins, which are of
increasing utility.32 Herein we disclose the realisation of this
strategy in an ‘organocatalyst-mediated protein aldol ligation’
(OPAL) that enables site-selective formation of stable C–C
bonds to protein aldehydes 2 at neutral pH at internal sites
within folded proteins, and at the N-terminus (Fig. 1, enamine
activation mode). OPAL is a stand-alone protein bio-
conjugation reaction which is highly efficient and complete
within 1 h using as few as 2 equivalents of simple aldehyde
probe. Additionally the selectivity of the ligation is also
demonstrated in complex mixtures through the affinity puri-
cation of a pH sensitive protein from a cell lysate. Further-
more, we establish that the b-hydroxy aldehyde OPAL product
3 can subsequently take part in an organocatalyst-mediated b-
hydroxy oxime ligation unexpectedly accelerated at neutral
over acidic pH, affording access to dual differentially modi-
ed proteins 4. The utility of this tandem method is show-
cased in the ‘chemical mimicry’ of a dual post-translationally
lipidated surface protein, integral to the pathogenesis of
Leishmaniasis.33Fig. 1 Schematic representation of organocatalyst-mediated protein ald
5586 | Chem. Sci., 2018, 9, 5585–5593Results and discussion
Feasibility studies on proteins
To establish conditions for the OPAL we studied two model
protein systems, haem co-factor containing horse heart
myoglobin 5, and disulde bond containing thioredoxin 6, both
bearing non-enolisable N-terminal a-oxo aldehydes34,35 (for
aldehyde installation methods see ESI Fig. 1†). Preliminary
ligations in phosphate buffer (PB) afforded full conversion to
the desired b-hydroxy protein aldehydes within 6 h at neutral
pH with 100 mM L-proline organocatalyst 1, using butyralde-
hyde 7 as an aldol donor (Fig. 2a). Importantly, only a single
organocatalyst-dependent aldol modication occurred, con-
rming the expected stability of the b-hydroxy aldehyde motif to
further aldol reactions.36 Additionally UV/Vis spectroscopic
measurements of the haem group in the modied myoglobin
demonstrated no compromise to the protein's tertiary structure
had occurred (ESI Fig. 2†) and trypsin digest and LC-MS/MS
analysis of the resulting peptide fragments conrmed the site-
selective nature of OPAL (ESI Fig. 3†).Optimisation on peptides and proteins
Encouraged by the biological compatibility and site-selectivity
of these preliminary ligations, attention next turned to opti-
mising OPAL by focusing on the choice of organocatalyst and
aldehyde donor species. We screened a panel of secondary
amines to investigate their ability to catalyse the ligation using
the well studied model peptide substrate a-oxo-aldehyde-
LYRAG 8 and butyraldehyde 7, and determined second order
rate constants for each catalyst at 1, 10, and 25 mM loadings
(Fig. 2b, see ESI Table 1,† ESI Fig. 4† for MS/MS analysis, and
the ESI† page S35 for a discussion on stereochemistry). There
was a 60-fold range in the magnitude of the rate constants
across the panel with tetrazole 9 exhibiting the highest
value.37,38 Similar reactivity correlations were also evident using
a protein substrate (ESI Fig. 5†). Further peptide screens
demonstrated that the nature of the a-carbon substituent of the
aldehyde donor also signicantly affected the rate of ligation, as
in the presence of L-proline 1 and tetrazole 9, donors such as
phenylacetylaldehyde 10, bearing an aryl substituent, reactedol ligation (OPAL) and its application.
This journal is © The Royal Society of Chemistry 2018
Fig. 2 (a) Left: OPAL bioconjugations using butyraldehyde 7 as an aldol donor andmyoglobin 5 and thioredoxin 6 as aldol acceptors. Right: Mass
spectrum traces of hydrated protein aldehyde starting material, and products following OPAL. (b) Aldol organocatalyst screen using butyral-
dehyde 7 and phenylacetaldehyde 10 as donors, with observed second order rate constants for individual organocatalysts colour coded red
(slowest) < pale orange < dark orange < light green < dark green (fastest).
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View Article Online240-fold faster than aldehyde donors bearing alkyl substitu-
ents. Overall, the rate constant of 24 M1 s1 using tetrazole 9
compares favorably with the fastest aldehyde bioconjugations
reported in the literature at any pH,24,39 demonstrating that
judicious choice of both organocatalyst and donor species is
essential for achieving optimal rates of ligation.Site-selective functionalisation of proteins
Next we set out to explore the scope of these optimised condi-
tions in the site-selective bioconjugation of a range of proteins
using functionalised a-aryl aldehyde probes. Guided by a desire
to simplify protein chemical modication procedures, we
designed a practical synthetic route to access a-aryl substituted
aldehyde donors bearing functional tags, including a uores-
cent label 11, a biotin affinity tag 12, a folate targeting moiety
13, and a bioorthogonal azide handle 14 (Fig. 3a). Probes
bearing 1,2 amino-alcohols 15 were constructed using solid
phase peptide synthesis (SPPS) from readily available building
blocks, and unmasked using a biologically compatible period-
ate oxidation to reveal the desired aldehyde (Fig. 3b). These
aldehyde probes were then deployed in the site-selective OPAL
modication of a variety of a-oxo aldehyde containing proteins
using 25 mM tetrazole 9 at neutral pH (Fig. 3c). Thioredoxin,
myoglobin and hydrophilic acylated surface protein A (HASPA)
from Leishmania donovani,33 all bearing a-oxo aldehydes at their
N-termini, were modied in quantitative conversion within 1 h
using 2–20 equivalents of aldehyde probe, with no modication
observed on proteins that did not bear the required aldehyde
functionality (see ESI† Section 6 for seven further protein bio-
conjugation examples). GFP protein bearing an a-oxo aldehydeThis journal is © The Royal Society of Chemistry 2018in addition to a bioorthogonal strained alkyne (cyclooctyne-
lysine) at position 39 was also compatible with the OPAL
conditions and quantitatively modied with both folate
(Fig. 3c), and biotin tags (see ESI† page S58). Additionally OPAL
linkages showed no liability aer incubation in 25 mM PB pH
7.5 over 72 hours at 37 C (ESI Fig. 6†).Functionalisation of proteins at internal residues and in cell
lysate
We also demonstrated the compatibility of OPAL in bio-
conjugations at internal sites within folded green uorescent
protein (GFP) and superfolder GFP (sfGFP) (Fig. 4a, ESI Fig. 7†).
a-Oxo aldehydes were rst quantitatively installed into the
proteins at neutral pH using a biocompatible Pd-mediated
decaging (1 equivalent for 1 h)27 of an incorporated unnatural
thiazolidine-lysine (ThzK) amino acid, recently developed in our
lab. Both internal aldehydes were then functionalised using
OPAL to install azide handles at position 39 of GFP and position
150 of sfGFP in 1 h using aldehyde probe 14 with no observable
loss of uorescence. Furthermore we demonstrated the
compatibility of both the Pd-mediated decaging and OPAL
modication in cell lysate (Fig. 4b, ESI Fig. 8–10† for uncropped
gels). Following expression of the ThzK containing GFP in E.
coli, the cell lysate was subjected to a 1 h Pd-mediated decaging
followed by a further 1 h OPAL using biotin tag 12 at neutral pH.
The lysate was then loaded onto an avidin affinity column,
which was washed prior to elution with 2 mM biotin to afford
the OPAL biotinylated GFP protein (see ESI† page S16 for
protein recovery at each step). The ability to selectively pull-
down only the a-oxo aldehyde containing GFP from the lysateChem. Sci., 2018, 9, 5585–5593 | 5587
Fig. 3 (a) OPAL probe precursors bearing functional tags. (b) Mild NaIO4 unmasking of a-aryl aldehyde probes. (c) OPAL functionalization of N-
terminal a-oxo aldehyde containing proteins (50–250 mM), using probes 11–14 (0.5–1.5 mM).
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View Article Onlinein a 2 h procedure showcases the selectivity and efficiency of
OPAL for the modication of an internal aldehyde in folded GFP
within a mixture of proteins, and the retention of GFP uores-
cence (which is quenched at mildly acidic pH (ref. 40)) also
highlights the signicant advantage of functionalisation at
neutral pH.
Optimising bi-functional modication
As previously observed by Macmillan in small molecule cross
aldol reactions,36 the b-hydroxy aldehyde product of the OPAL
displayed no reactivity in further aldol reactions.41 So we next
determined whether this aldehyde was reactive under alterna-
tive conditions which would enable construction of challenging
but coveted differentially bi-functionalised proteins (Fig. 5),
which have limitless potential applications.32,42,43 Using peptide
b-hydroxy aldehyde-LYRAG 16, we screened the reactivity of the
b-hydroxy aldehyde as an electrophilic partner in two high
yielding literature bioconjugation reactions, the iso-Pictet–
Spengler ligation44 and the 2-amino benzamidoxime (ABAO)
ligation45 (both with optimal reactivity at acidic pH). Although
conversion to bi-functionalised product was observed, yields
were disappointingly low (ESI Fig. 11†), emphasising the rela-
tive stability of the b-hydroxy aldehyde moiety compared to
other aldehydes previously used in bioconjugation studies.25We
therefore turned our attention to the classical acid-catalysed
oxime ligation (pH 4.5 optimum), which proceeds more slowly
at neutral pH but can be accelerated by the addition of aniline5588 | Chem. Sci., 2018, 9, 5585–559317 as an organocatalyst.46 Gratifyingly, in studies using b-
hydroxy aldehyde-LYRAG 16 and an aminooxy nucleophile at
pH 4.5 we achieved 61% conversion to bi-functionalised
product 18 in the presence of aniline organocatalyst 17. Unex-
pectedly however, the conversion to the b-hydroxy oxime
product 18 was further increased to 95% when the reaction was
performed at pH 7.5 (Fig. 5a, aniline Schiff base activation
mode), which is a reversal of the precedent for oxime formation
with other aldehyde handles.46 This trend was again evident
when screening alternative aniline organocatalysts which have
been previously reported for hydrazone/oxime ligation,47 as well
as with alternative peptide and protein b-hydroxy aldehyde
substrates (ESI Fig. 12†), suggesting a general trend in reactivity
and improved biological compatibility. Akin to observations
made for imine formation at ortho-substituted aromatic alde-
hydes in water,48 this reversal may be governed by intra-
molecular H-bonding between the b-hydroxy group and the
protonated aldehyde or aniline Schiff base intermediates
formed en route to oxime formation, and merits further
investigation.
Bi-functional modication of proteins through b-hydroxy
oxime ligations
Having established an unexpected reversal in pH dependence
for the rate of oxime formation we subsequently demonstrated
the potential utility of the organocatalyst-mediated b-hydroxy-
oxime ligation in tandem with OPAL for the construction ofThis journal is © The Royal Society of Chemistry 2018
Fig. 4 (a) Incorporation of internal a-oxo aldehydes through Pd-mediated decaging, and tandem OPAL functionalisation of proteins. ESI-MS
traces of OPAL products following spectra deconvolution. (b) Pd-mediated decaging and OPAL biotinylation in cell lysate. SDS-PAGE lane 1:
ladder; lane 2: cell lysate post OPAL; lanes 3, 4, 5: biotin elution.
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View Article Onlinedual N-terminal functionalised proteins using both a biotin
aminooxy affinity handle 19, and a polyethylene glycol (PEG)
aminooxy reagent 20 (Fig. 5b). A two-step organocatalyst-
mediated tandem modication of thioredoxin 6 was achieved
at neutral pH, rstly using OPAL to quantitatively install
a uorescent label into the protein using 25 mM tetrazole 9 and
probe 11, followed by tandem oxime ligation under optimised
reaction conditions of 10 mM p-anisidine 21 organocatalyst in
PB (50 mM, pH 7.5) and biotin affinity handle 19, to afford
differentially functionalised thioredoxin 22 (Fig. 5c, ESI Fig. 13†
for uncropped gels). SDS-PAGE and Western blot (anti-biotin-
alkaline phosphatase antibody detection) analysis of the
unmodied a-oxo aldehyde thioredoxin 6 (lane 3), uorescent
OPAL product 23 (lane 4), and the bi-functional construct 22
(lane 5), demonstrated that the protein could be detected by
uorescence only aer OPAL modication with aldehyde probe
11 (lane 4), and by uorescence and Western blotting only aer
tandem oxime formation using biotin 19 (lane 5). Under iden-
tical organocatalyst conditions thioredoxin could also modied
with both an azide and biotin probe with detection of the bi-
functionalised product 24 by Western blot (Fig. 5d, ESI
Fig. 14†) as well as myoglobin with both azide and biotin (ESI†
page S67). Fluorescent myoglobin OPAL product 25 was also
further functionalised by PEGylation (Fig. 5e, ESI Fig. 15†),
a strategy used for increasing the circulatory lifetime of thera-
peutic proteins. Following treatment with aminooxy probe 20,
PEGylated uorescent protein 26 (lane 4) was characterised
using SDS-PAGE by an increase inmolecular weight in over bothThis journal is © The Royal Society of Chemistry 2018unmodied 5 (lane 2) and uorescent myoglobin 25 (lane 3).
Additionally, we noted the b-hydroxy oxime linkages resulting
from tandem bioconjugation reactions, showed no degradation
over 30 days at neutral pH (ESI Fig. 16†).Towards chemical mimicry of natural dual PTMs of HASPA
Finally, we sought to explore the suitability of the tandem OPAL-
oxime ligation for the ‘chemical mimicry’ of a natural dual post-
translational modication (PTM) integral to the pathogenesis of
the neglected tropical disease Leishmaniasis. Hydrophilic acyl-
ated surface proteins (HASPs) are present in all human infective
Leishmania parasites. They are highly immunogenic and form the
basis of a visceral leishmaniasis vaccine currently undergoing
clinical trials in humans.49 Their expression is stage regulated
during human infection, however the exact role they play in the
parasite lifecycle has yet to be determined.33 Non-classically,
HASPA is dually acylated at the N-terminus (Fig. 6, top) with
bothmyristoyl 27 (at Gly1) and palmitoyl 28 (at Cys4) lipids, PTMs
which are thought to govern its ability to associate with plasma
membranes50 but not fully rationalised. Whilst co-translational
myristoylation of HASPA by the parasite N-myristoyl transferase
(NMT) can be recapitulated in vitro, the S-palmitoyltransferase is
unknown and the Cys4 containing protein is prone to precipita-
tion, which has limited recombinant access to natural dual lipi-
dated protein for further study. We therefore designed a strategy
using our tandem biocompatible ligations to chemically mimic
the structural modications of HASPA for the rst time (Fig. 6,
bottom), and provide access to a dual lipidated construct.Chem. Sci., 2018, 9, 5585–5593 | 5589
Fig. 5 (a) pH dependence of b-hydroxy oxime ligation using aniline organocatalysts. (b) Schematic representation of organocatalyst-mediated
oxime ligation of protein b-hydroxy aldehydes. (c) Product 22 of tandem organocatalyst-mediated bioconjugations of thioredoxin 6 and
fluorescent OPAL product 23, analysed by SDS-PAGE and Western blot. (d) Product 24 of tandem organocatalyst-mediated bioconjugation of
thioredoxin 6 analysed by Western blot. Lane 1 in (c) and (d) ¼ molecular weight ladder; lane 2 in (c) and (d) ¼ wt thioredoxin, prior to a-oxo
aldehyde installation; lane 3 in (c) and (d) ¼ a-oxo thioredoxin 6; lane 4 in (c) and (d) ¼ thioredoxin OPAL products; lane 5 in (c) and (d) ¼
thioredoxin OPAL-b-hydroxy oxime products. (e) Product 26 of tandem organocatalyst-mediated bioconjugations of myoglobin 5 analysed by
SDS-PAGE. Lane 1 ¼molecular weight ladder; lane 2 ¼ a-oxo myoglobin 5; lane 3 ¼OPAL-myoglobin 25; lane 4 ¼ Top band: OPAL-b-hydroxy
oximemyoglobin 26; bottom band: presumedOPAL-myoglobin startingmaterial 25with non-covalent association of 20. Conditions for tandem
b-hydroxy oxime ligations: proteins 25–50 mM, 15 mM 19 or 20, 10 mM 21, PB (50 mM), pH 7.5, 37 C, 18–42 h.
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View Article OnlineUsing myristoyl aldehyde 29 as donor and recombinantly
expressed Leishmania donovani HASPA bearing an N-terminal a-
oxo aldehyde as a substrate (C4S mutant, see ESI Fig. 17†) weFig. 6 Schematic representation of native dual PTM of Leishmania H
mediated tandem bioconjugation (bottom).
5590 | Chem. Sci., 2018, 9, 5585–5593rstly used OPAL to construct a chemical mimic 30 of the
natural myristoylated protein at neutral pH in quantitative
conversion (ESI-MS characterisation, Fig. 7b). To establish thatASPA (top), and proposed ‘chemical mimicry’ using organocatalyst-
This journal is © The Royal Society of Chemistry 2018
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View Article Onlinethis bioconjugate structurally mimics myristoylation we used
NMR spectroscopy to characterise both the unmodied HASPA
31 and enzymatically myristoylated HASPA 27, lipidated using
puried recombinant N-myristoyl transferase.51 Following
resonance assignment of backbone nuclei (ESI Fig. 18†),
comparison of the 2D (1H, 15N) HSQC spectra revealed that
myristoylation of the native protein caused exchange broad-
ening of resonances for residues near the N-terminus,
including Y3, S4, T5 and S8 (Fig. 7a, le panel). Subsequent
NMR characterisation of the chemically myristoylated HASPA
30 was also then performed and the HSQC spectra revealed to
be highly comparable to that of the enzymatically modied
protein 27 (Fig. 7a, right panel), with residues near the N-
terminus also displaying the characteristic exchange broad-
ening following modication. These data therefore demon-
strate that OPAL modication of HASPA replicates the in vitro
solution properties and structure of the enzymatically modi-
ed protein, and also highlight the simplicity of the OPAL
procedure for use in the chemical mimicry of protein myr-
istoylation, which in this example requires only three afford-
able commercial reagents, sodium periodate for aldehyde
installation (see ESI Fig. 1†), and aldehyde 29 and organo-
catalyst 9 for the OPAL.Fig. 7 (a) Regions of 2D (1H, 15N) HSQC spectra of [15N] labelled HASPA
myristoylated (red) HASPA 27 (left). Comparison of unmodified 31 (grey) a
assignments are indicated. Unassigned peaks are denoted by asterisks. (b)
myristoylated HASPA 30 (left), and dual modified HASPA mimic 33 (right)
page S83 aldol condensation product with loss of H2O is also visible. Nota
observed in this example. (c) SDS-PAGE analysis of liposome sedimenta
myristoylated HASPA 30 (central panel, myristoylated), and dual modified
a suspension of PC:Ch liposomes and dialysed in the presence of deterg
some pellet (P) were analyzed by SDS-PAGE (M¼molecular weight ladde
controls in the absence of protein or liposome, and SDS-PAGE analysis.
This journal is © The Royal Society of Chemistry 2018To begin to investigate the potential function of in vivo dual
modication of HASPs, we next subjected the OPAL myristoy-
lated HASPA 30 to tandem organocatalyst-mediated b-hydroxy
oxime ligation using palmitoyl aminoxy 32. The dual modied
product 33, a chemical mimic of myristoylation and palmitoy-
lation, was also characterised by ESI-MS (Fig. 7b). Finally both
the OPAL myristoylated HASPA 30 and this dual modied
HASPA 33 were characterised using time course liposome
sedimentation assays to assess their capacity to bind to model
biological membranes (Fig. 7c). SDS-PAGE analysis revealed
that over a 30 h period both lipid modied HASPs displayed
substantially greater levels of in vitro association to membranes
than the unmodied HASPA 31 (Fig. 7c) and approximately
twice as much protein was bound to the membrane when
HASPA was dual lipidated in 33 compared to mono myr-
istoylation in 30 (ESI Fig. S22†). Results from this in vitro
‘chemical model system’ therefore substantiate the notion that
the in vivo role of the lipid PTMs is to facilitate attachment of
HASPA to parasite membranes and determine its localisation to
the cell surface,50 and emphasise that two lipid modications
may be required to maximise in vivo binding, with the caveat
that further in-depth functional comparison of single and dual
lipidated HASPs in cellulo is still warranted.(C4S mutant). Comparison of unmodified 31 (grey) and enzymatically
nd chemically myristoylated (red) HASPA 30 (right). (1H, 15N) Resonance
ESI-MS characterisation following spectra deconvolution of chemically
, note only peaks for 30 and 33 are visible, in the magnified spectra on
bly in all OPAL reactions performed, aldol condensation product is only
tion assays over 30 h. 20 mg unmodified HASPA 31 (left panel), OPAL
chemical mimic 33 HASPA (right panel, dual acylated), were added to
ent and then sedimented. The supernatant (S) and resuspended lipo-
r). See ESI Fig. 19–22† for associated preparation of liposomes, negative
Chem. Sci., 2018, 9, 5585–5593 | 5591
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View Article OnlineConclusion
In conclusion, we have validated the OPAL as a powerful stand-
alone C–C forming bioconjugation strategy using simple alde-
hyde probes for themild site-selective modication of a range of
proteins at both internal and N-terminal sites demonstrating
exibility in both positioning and functionalisation. We also
demonstrated the compatibility and selectivity of both Pd-
mediated decaging of internal a-oxo aldehydes and subse-
quent OPAL modication in a mixture of proteins within cell
lysate to enable affinity pull-down of GFP, which maintains its
uorescence as a consequence of purication at neutral pH. We
anticipate the potential applicability and simplicity of this
strategy may also serve to nucleate further organocatalyst-
mediated protein modication studies.
In contrast to other protein bioconjugations, OPAL not only
‘survives’ but ‘thrives’ in biocompatible conditions. This is
because at aqueous neutral pH the b-hydroxy aldehyde product
of the OPAL predominates over the enal (aldol condensation)
product. The b-hydroxy group of this newly installed aldehyde
prevents further aldol reactions facilitating a single site-
selective modication and in an additional benet serves as
a “pH switch” for a novel tandem b-hydroxy oxime ligation
which is unexpectedly accelerated at neutral pH over acidic pH.
Oxime ligations are perhaps the most widely used protein
bioconjugation reaction,47 but limited in that they are most
efficient at acidic pH even when using aniline organocatalysts.
The presence of the b-hydroxy group seemingly alters this
acidic bias and constitutes a new aldehyde scaffold for bio-
conjugations, which has an in-built preference to react, and is
stable at neutral pH.
Finally we utilised OPAL in the chemical mimicry of N-
terminal myristoylation of a HASP protein integral to the
pathogenesis of Leishmaniasis and demonstrated the ability to
mimic the structural effects of enzymatic myristoylation
through characterisation by protein NMR. Subsequent chem-
ical palmitoylation by a tandem b-hydroxy oxime ligation
generated a construct that also mimics the previously inac-
cessible natural dual modied protein, and furthermore was
used for exploring the effects of single vs. dual lipid modica-
tion on binding to membranes. Notably this strategy may lend
itself to the in vitro study of other proteins bearing multiple
post-translational lipid modications52 and may also prove
broadly applicable in the functionalisation and immobilisation
of other biomolecules.Author contributions
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